BCHT(688276)
Search documents
百克生物-推动高质量发展 提振投资者信心——2025年吉林辖区上市公司投资者网上集体接待日【全景路演】
2024-10-31 00:57
Summary of the Conference Call Industry or Company Involved - The conference call pertains to the **Jilin Province listed companies** and their efforts to enhance investor confidence and communication through an online collective reception day event in 2025 [1][10]. Core Points and Arguments - The event is organized by the **Jilin Securities Industry Association** in collaboration with **Shenzhen Panorama Network Co., Ltd.**, aimed at improving the intellectual level of listed companies in the Jilin region and establishing a good communication mechanism between companies and investors [1][10]. - High-level executives from various listed companies, including chairpersons, general managers, financial directors, and board secretaries, participated in the online interaction with investors, addressing concerns regarding the **2024 annual reports**, risk prevention, investor protection, and sustainable development [1][10]. - The event utilized internet virtual space for face-to-face communication, allowing investors to gain a comprehensive understanding of the participating companies [3][10]. - A total of **872 questions** were answered by company representatives during the event, indicating a strong interaction between listed companies and investors [10]. Other Important but Possibly Overlooked Content - The event emphasized the importance of maintaining open channels for communication between listed companies and investors, encouraging ongoing dialogue beyond the event [10]. - The initiative reflects a broader trend in the industry towards enhancing transparency and responsiveness to investor inquiries, which is crucial for building trust and confidence in the market [1][10].
中钢国际-推动高质量发展 提振投资者信心——2025年吉林辖区上市公司投资者网上集体接待日【全景路演】
2024-10-31 00:57
Summary of the Conference Call Industry or Company Involved - The conference call pertains to the **Jilin Province listed companies** and their efforts to enhance investor confidence and communication through an online collective reception day event in 2025 [1][10]. Core Points and Arguments - The event is organized by the **Jilin Securities Industry Association** in collaboration with **Shenzhen Panorama Network Co., Ltd.**, aimed at improving the intellectual level of listed companies in the Jilin region and establishing a good communication mechanism between companies and investors [1][10]. - High-level executives from various listed companies, including chairpersons, general managers, financial directors, and board secretaries, participated in the online interaction with investors, addressing concerns regarding the **2024 annual reports**, risk prevention, investor protection, and sustainable development [1][10]. - The event facilitated a total of **872 questions** answered by company representatives, showcasing effective interaction between listed companies and investors [10]. Other Important but Possibly Overlooked Content - The event utilized multiple channels for real-time reporting, including video live streaming, text reporting, and on-site images, to ensure comprehensive coverage and engagement [1]. - The ongoing communication channels will remain open for investors to continue raising their concerns through the **Panorama Network** platform, indicating a commitment from Jilin listed companies to address investor information needs promptly [10].
致远新能-推动高质量发展 提振投资者信心——2025年吉林辖区上市公司投资者网上集体接待日【全景路演】
2024-10-31 00:57
Summary of the Conference Call Industry or Company Involved - The conference call pertains to the **Jilin Province listed companies** and their efforts to enhance investor confidence through an online collective reception day event in 2025 [1][10]. Core Points and Arguments - The event is organized by the **Jilin Securities Industry Association** in collaboration with **Shenzhen Panorama Network Co., Ltd.**, aimed at improving the intellectual level of listed companies in Jilin and establishing a good communication mechanism between companies and investors [1][10]. - High-level executives from various listed companies, including chairpersons, general managers, financial directors, and board secretaries, participated in the online interaction with investors, addressing concerns regarding the **2024 annual reports**, risk prevention, investor protection, and sustainable development [1][10]. - The event utilized internet virtual space for face-to-face communication, allowing investors to gain a comprehensive understanding of the participating companies [3][10]. - A total of **872 questions** were answered by company representatives during the event, indicating a strong interaction between listed companies and investors [10]. Other Important but Possibly Overlooked Content - The event emphasizes the importance of maintaining open channels for communication between listed companies and investors, suggesting that the interaction will continue beyond the event through platforms like **Panorama Network** [10]. - The initiative reflects a broader trend in the industry towards enhancing transparency and responsiveness to investor inquiries, which is crucial for building trust and confidence in the market [1][10].
益盛药业-推动高质量发展 提振投资者信心——2025年吉林辖区上市公司投资者网上集体接待日【全景路演】





2024-10-31 00:57
Summary of the Conference Call Industry or Company Involved - The conference call pertains to the **Jilin Province listed companies** and their efforts to enhance investor confidence through an online collective reception day event in 2025 [1][10]. Core Points and Arguments - The event is organized by the **Jilin Securities Industry Association** in collaboration with **Shenzhen Panorama Network Co., Ltd.**, aimed at improving the intellectual level of listed companies in Jilin and establishing a good communication mechanism between companies and investors [1][10]. - High-level executives from various listed companies, including chairpersons, general managers, financial directors, and board secretaries, participated in the online interaction with investors, addressing concerns regarding the **2024 annual reports**, risk prevention, investor protection, and sustainable development [1][10]. - The event utilized internet virtual space for face-to-face communication, allowing investors to gain a comprehensive understanding of the participating companies [3][10]. - A total of **872 questions** were answered by company representatives during the event, indicating a strong interaction between listed companies and investors [10]. Other Important but Possibly Overlooked Content - The event emphasized the importance of maintaining open channels for communication between listed companies and investors, encouraging ongoing dialogue beyond the event [10]. - The initiative reflects a broader trend in the industry towards enhancing transparency and responsiveness to investor inquiries, which is crucial for building trust and confidence in the market [1][10].
长春一东-推动高质量发展 提振投资者信心——2025年吉林辖区上市公司投资者网上集体接待日【全景路演】
2024-10-31 00:57
各位嘉宾各位投资者各位网友大家下午好 推动高质量发展提振投资者信心2025年吉林辖区上市公司投资者网上集体接待日活动热情欢迎您的参与本次活动是由吉林省证券业协会主办深圳市全景网络有限公司协办感谢您的关注全景网全景路演将对本次活动进行全程关注利用视频直播文字报道现场图片等多渠道对活动进行现场实时报道 为切实提高吉林辖区上市公司智力水平建立公司和投资者良好沟通机制便于投资者全面深入了解辖区上市公司发展情况和经营成果由吉林省证券业协会联合深圳市全景网络有限公司共同举办的推动高质量发展提振投资者信心2025年吉林辖区上市公司投资者网上集体接待日活动 活动组织辖区各上市公司董事长总经理财务总监董事会秘书等高管人员利用投资者关系互动平台与广大投资者进行集中在线交流在本次活动中吉林辖区上市公司高管人员将通过网络在线交流形式就2024年年报防控风险投资者保护可持续发展等各位所关心的问题 通过互动平台和投资者进行一对多形式的沟通和交流下面请允许我向大家介绍出席今日活动的吉林辖区的49家上市公司他们是奥莱德奥普光电百克生物长白山长春高新长春燃气长春伊东迪瑞医疗东北证券富澳股份浩辰医疗华为电子 吉大通信 吉大证源 吉电股份吉林敖东 ...
受带状疱疹疫苗销量下滑拖累 百克生物第三季度收入跌超40%
Cai Lian She· 2024-10-25 11:16AI Processing
《科创板日报》10月25日讯(记者 郑炳巽) 25日晚间,知名疫苗公司百克生物(688276.SH)正式发 布2024年第三季度报告。报告期内,由于带状疱疹减毒活疫苗销量减少,百克生物第三季度实现营收 4.08亿元,同比下降40.37%,归母净利润1.07亿元,同比下降51.41%。 受第三季度业绩拖累,百克生物1-9月份累计实现营收10.26亿元,同比下降17.47%,归母净利润2.44亿 元,同比下降26.19%。若不含第三季度业绩,百克生物上半年实现营收6.18亿元,同比增长10.50%,归 母净利润1.38亿元,同比增长23.54%。 作为一家专业从事人用疫苗研发、生产、销售的企业,百克生物目前拥有3款已获批上市的疫苗产品, 包括水痘疫苗、鼻喷流感疫苗,以及带状疱疹疫苗。其中,带状疱疹疫苗在2023年年初获得国家药监局 批准上市,百克生物也因此打破了国内带状疱疹预防产品由进口疫苗垄断的局面。 在带状疱疹疫苗上市之前,百克生物的最大收入来自于水痘疫苗。以2021年与2022年为例,百克生物实 现营收12.02亿元、10.71亿元,其中水痘疫苗的收入分别为10.20亿元、9.57亿元,占整体营收比例分别 ...
百克生物:中信证券关于百克生物使用自有资金垫付募投项目所需资金并以募集资金等额置换、将部分暂时闲置募集资金以定期存款方式存放的专项核查意见
2024-10-25 08:06
中信证券股份有限公司(以下简称"保荐机构")担任长春百克生物科技股 份公司(以下简称"百克生物"或"公司")首次公开发行股票并上市持续督导 期间的保荐机构,根据《证券发行上市保荐业务管理办法》《上海证券交易所科 创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号— —规范运作》等有关规定,对公司使用自有资金垫付募投项目所需资金并以募集 资金等额置换、将部分暂时闲置募集资金以定期存款方式存放的事项进行了核查, 核查情况如下: 中信证券股份有限公司 关于长春百克生物科技股份公司 使用自有资金垫付募投项目所需资金并以募集资金等额置换、 将部分暂时闲置募集资金以定期存款方式存放的专项核查意见 一、募集资金基本情况 经中国证券监督管理委员会《关于同意长春百克生物科技股份公司首次公开 发行股票注册的批复》(证监许可[2021]1594号)的同意,公司采用向社会公开 发行方式发行人民币普通股(A股)41,284,070股,发行价格为每股36.35元,募 集资金总额1,500,675,944.50元,扣除承销费、保荐费、审计费、律师费、信息披 露等发行费用104,881,526.35元后,实际募集资金净额 ...
百克生物:长春百克生物科技股份公司关于使用自有资金垫付募投项目所需资金并以募集资金等额置换的公告
2024-10-25 08:06
证券代码:688276 证券简称:百克生物 公告编号:2024-036 长春百克生物科技股份公司 关于使用自有资金垫付募投项目所需资金 并以募集资金等额置换的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 长春百克生物科技股份公司(以下简称"公司")于 2024 年 10 月 24 日召开 第五届董事会第二十七次会议,第五届监事会第二十一次会议,审议通过了 《关于使用自有资金垫付募投项目所需资金并以募集资金等额置换的议案》。公 司保荐机构中信证券股份有限公司(以下简称"保荐机构")对本事项出具了 明确的核查意见。具体情况公告如下: 一、募集资金基本情况 经中国证券监督管理委员会《关于同意长春百克生物科技股份公司首次公 开发行股票注册的批复》(证监许可[2021]1594号)的同意,公司采用向社会公 开发行方式发行人民币普通股(A股)41,284,070股,发行价格为每股36.35元, 募集资金总额1,500,675,944.50元,扣除承销费、保荐费、审计费、律师费、信 息披露等发行费用104,881,526.35元 ...
百克生物:长春百克生物科技股份公司关于将部分暂时闲置募集资金以定期存款方式存放的公告
2024-10-25 08:06
证券代码:688276 证券简称:百克生物 公告编号:2024-037 长春百克生物科技股份公司 关于将部分暂时闲置募集资金以定期存款方式存放的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 长春百克生物科技股份公司(以下简称"公司")在保证不影响公司募 集资金投资计划正常进行的前提下,拟将部分暂时闲置募集资金以定期存款方式 存放。 公司计划以定期存款方式存放部分暂时闲置募集资金,最高额度不超过 人民币1.5亿元(含本数),在前述额度范围内,资金可以循环滚动使用。 公司募集资金将按照募投项目整体进度安排合理、及时使用,将部分暂 时闲置募集资金以定期存款方式存放不会影响募投项目的建设。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意长春百克生物科技股份公司首次公开 发行股票注册的批复》(证监许可[2021]1594号)的同意,公司采用向社会公开发 行方式发行人民币普通股(A股)41,284,070股,发行价格为每股36.35元,募集 资金总额1,500,675,944.50元,扣除承销费、保荐 ...
百克生物(688276) - 2024 Q3 - 季度财报
2024-10-25 08:06
Financial Performance - The company's revenue for Q3 2024 was CNY 407,611,069.81, a decrease of 40.37% compared to the same period last year[2]. - Net profit attributable to shareholders was CNY 106,765,322.76, down 51.41% year-on-year[2]. - The net profit after deducting non-recurring gains and losses was CNY 109,563,615.52, a decline of 50.06% compared to the previous year[2]. - Total operating revenue for the first three quarters of 2024 was CNY 1,026,012,316.59, a decrease of 17.5% compared to CNY 1,243,193,321.15 in the same period of 2023[16]. - Net profit for the first three quarters of 2024 was CNY 244,369,819.42, a decline of 26.1% from CNY 331,093,189.21 in the same period of 2023[16]. - The net profit for the third quarter of 2024 was CNY 247,493,581.24, down 31.9% from CNY 363,507,360.41 in the third quarter of 2023[25]. - The company reported a total profit of CNY 282,513,112.45 for the third quarter of 2024, down from CNY 405,711,673.11 in the third quarter of 2023, reflecting a decline of approximately 30.4%[25]. Research and Development - R&D investment totaled CNY 30,973,332.82, a decrease of 21.28% year-on-year, while the ratio of R&D investment to revenue increased by 1.84 percentage points to 7.60%[3]. - Research and development expenses for the first three quarters of 2024 amounted to CNY 116,503,270.72, compared to CNY 136,687,474.68 in 2023, indicating a decrease of 14.8%[16]. - Research and development expenses for the first three quarters of 2024 were CNY 116,586,639.97, a decrease of 7.4% compared to CNY 126,006,417.52 in the same period of 2023[24]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was CNY 229,104,857.16, an increase of 91.30% year-on-year[7]. - Cash generated from operating activities was CNY 943,560,340.61 in the first three quarters of 2024, an increase of 22.7% from CNY 768,530,316.02 in 2023[18]. - The net cash flow from operating activities for Q3 2024 was CNY 229,104,857.16, an increase of 91.5% compared to CNY 119,764,590.55 in Q3 2023[19]. - Total operating cash inflows amounted to CNY 1,006,246,535.96, up from CNY 880,133,700.46 in the same period last year[19]. - Cash and cash equivalents at the end of Q3 2024 were CNY 272,254,690.37, down from CNY 454,466,166.62 at the end of Q3 2023[20]. - The company's cash and cash equivalents decreased to RMB 277,889,806.27 from RMB 442,179,928.33, representing a decline of about 37.1%[12]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,313,956,757.40, reflecting a 5.31% increase from the end of the previous year[3]. - The company's total assets reached RMB 5,313,956,757.40, an increase from RMB 5,046,237,662.74 at the end of 2023, reflecting a growth of approximately 5.3%[12]. - The company's total liabilities increased to RMB 1,066,780,990.96 from RMB 1,014,865,866.94, indicating a rise of about 5.1%[13]. - Total liabilities as of the end of the third quarter of 2024 were CNY 1,113,880,855.38, up from CNY 1,025,876,086.75 in 2023, representing an increase of 8.6%[16]. - The company's total liabilities rose to CNY 1,110,314,490.49 from CNY 1,021,189,232.11 year-over-year[23]. - The company's non-current assets totaled RMB 3,139,397,099.14, up from RMB 2,801,623,732.76, reflecting an increase of approximately 12.1%[13]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,466[8]. - Total equity attributable to shareholders reached CNY 4,200,075,902.02, an increase of 4.5% from CNY 4,020,361,575.99 in the previous year[16]. - The company's total equity increased to CNY 4,500,775,935.34 from CNY 4,317,937,847.49 year-over-year[23]. Operating Costs and Expenses - Total operating costs for the first three quarters of 2024 were CNY 731,232,689.54, down from CNY 832,335,257.40 in 2023, reflecting a reduction of 12.2%[16]. - The total operating expenses decreased to CNY 777,275,168.81 in the first three quarters of 2024, down from CNY 896,987,699.38 in the same period of 2023[27]. - The company’s sales expenses for the first three quarters of 2024 were CNY 380,401,013.16, down 14.3% from CNY 443,780,118.90 in the same period of 2023[24]. Government Support - The company received government subsidies amounting to CNY 1,321,742.23 during the reporting period[5].